Researchers found that excess pericardial fat increases the risk of heart failure, even after adjusting for established risk factors. High pericardial fat volume was associated with a double increase in risk for women and a 50% increase for men, according to the study published in the Journal of the American College of Cardiology.
Researchers at Mount Sinai found that SARS-CoV-2 can infect surface cells of the eye, revealing presence of infection-associated proteins and suppressed IFNβ. Ocular surface cells are susceptible to infection, while central cornea is less vulnerable.
A study published in Nature Genetics found 64 genome regions associated with an increased risk of bipolar disorder, providing new insights into the condition's underlying biology. The research also highlights potential therapeutic targets for future treatments.
Evinacumab reduces triglyceride levels by up to 82 percent in patients with severe hypertriglyceridemia and a history of hospitalizations for acute pancreatitis. The therapy also lowers the risk of recurrent acute pancreatitis, quality of life, and cardiovascular events.
A global commission led by Mount Sinai cardiologist Roxana Mehran recommends expanding education and health programs, research on women's heart disease, and prioritizing sex-specific interventions. The report aims to improve women's heart health outcomes worldwide by 2030.
A new study found that artificial food colorants like Red 40 and Yellow 6 can cause disease in mice with dysregulated immune systems, specifically colitis. Researchers are now investigating the potential impact on humans, given that similar cytokine IL-23 dysregulation is a factor in human inflammatory bowel disease.
Researchers used OCT angiography to image patients with sickle cell retinopathy and found that sequential imaging can help assess disease progression and treatment effectiveness. The study showed that untreated patients had more flickering blood vessels, indicating a higher risk of permanent blockage.
Scientists found that LCH is caused by senescent cells with a BRAF mutation, leading to inflammation and organ damage. A new study suggests using senolytics to treat the disease, offering hope for patients who have not responded to chemotherapy.
Researchers found that combining remdesivir with four HCV drugs boosts its antiviral activity by up to 10 times. This combination therapy could be a game changer for patients with COVID-19 who are not vaccinated or have waned immunity.
A new Mount Sinai study found that patients hospitalized with COVID-19 have a small but significant risk of developing heart failure, even without a previous history of heart disease or cardiovascular risk factors. The study's findings may prompt clinicians to monitor for signs of congestive heart failure more closely in these patients.
A Mount Sinai study of over 40,000 patients reveals that tranexamic acid use in high-risk patients does not increase complications such as deep vein blood clots or strokes. The study confirms prior findings and provides new insights into the safety of the drug when used in high-risk patients undergoing hip and knee replacement surgeries.
A longitudinal study of over 3,000 young Marines found that past COVID-19 infection does not completely protect against reinfection. Young people with previous infection can still catch the virus and transmit it to others.
Genetic ancestry data provides specific insights into disease risk and management, allowing for targeted interventions. The study found that 25% of BioMe participants had links to populations predisposed to certain genetic diseases.
A study of over 42,000 children found that mothers who took antidepressants during pregnancy were more likely to have children with affective disorders, but not due to the medication itself. The research suggests that parental mental illness may be the underlying cause.
A personalized cancer vaccine developed using a computational platform raised no safety concerns and showed potential benefit in patients with high-risk cancer recurrences. The vaccine was well-tolerated, with minor injection-site reactions, and demonstrated early potential benefits after administration.
A study published in Clinical Cancer Research found that specific gene signatures and immune cells can predict response to immunotherapy in bladder cancer patients. The researchers identified potential biomarkers for treatment resistance and new combination therapeutic approaches to overcome such resistance.
Researchers developed a new method to detect multiple types of DNA methylation in individual bacteria and the gut microbiome using nanopore sequencing. This breakthrough enables reliable methylation discovery and high-resolution microbiome analysis.
Researchers at Mount Sinai Hospital have identified genetic and cellular mechanisms underlying Crohn's disease, providing new insights for tailored treatments. By blocking the gp130 protein, they found that some patients may benefit from alternative therapies, complementing standard anti-TNF treatments.
Researchers found that autophagy selectively degrades PKA inhibitory subunit RIa, promoting mitochondrial metabolism and tumor cell growth. Suppression of AKAP11 levels in tumor cells prevents degradation and blocks PKA activation, inhibiting tumor cell growth.
Researchers discovered that the widely available Topotecan (TPT) inhibits inflammatory genes in the lungs of mice as late as four days after infection, improving infection outcomes. The drug, an FDA-approved Topoisomerase I inhibitor, could be a valuable global strategy for treating severe COVID-19 cases.
A Mount Sinai study found immunotherapy to be significantly less effective in liver cancer patients with non-alcoholic steatohepatitis (NASH), while also fueling tumor growth. The research highlights the need for refined therapeutic strategies to treat both tumors and underlying liver disease.
A study at The Mount Sinai Hospital found that a specific epigenetic modification, H3K79me2, mediates the lasting effects of early-life stress on adult stress vulnerability. A small-molecule inhibitor of this enzyme reversed increased susceptibility to lifelong stress in animal models.
Researchers at Mount Sinai found that a single shot of COVID-19 vaccine can provide immunity to individuals who have previously been infected by the virus. This could help stretch limited vaccine supplies and spare individuals from unnecessary side effects of a second dose.
Researchers at Mount Sinai Hospital have identified a new molecular driver of frontal circuit maturation that is essential for cognitive function. By selectively suppressing communication via nicotinic receptors in the frontal circuit, attention deficits caused by Fragile X syndrome can be prevented in animal models.
A study published in Environment International found that overweight children exposed to lead in utero and during their first weeks of life are at risk for poorer kidney function in adulthood. The research measured blood levels of lead during pregnancy and eGFR levels in children between 8-12 years old.
Researchers have identified ezogabine, a drug that opens potassium channels in the brain, as a promising new approach to treating depression. The study showed significant improvements in depressive symptoms and anhedonia in patients with depression.
A study found associations between urinary miRNAs and cardiorenal outcomes, including blood pressure and eGFR levels, in Mexican children. The researchers identified several miRNAs associated with kidney function, blood pressure, and electrolyte biomarkers.
A study published in Cancer found that nearly one-third of Black patients would not have qualified for liver cancer screening using common cirrhosis measures. The researchers also discovered that the tumors in Black patients tended to be larger, more numerous, and more invasive at diagnosis.
Mount Sinai researchers identified a neural pathway that detects errors and guides subsequent behavioral improvement, which is frequently dysregulated in psychiatric disorders. They also suggest that neurostimulation of this brain pathway could provide an important mechanism for attention adjustments following behavioral errors.
Researchers found that Polycomb repressive complex 1 (PRC1) and Polycomb repressive complex 2 (PRC2) maintain the skin-specific gene expression pattern necessary for proper development of the skin. The study suggests that targeting both complexes may be a more effective form of treatment for certain cancers.
A research team at Mount Sinai built a cellular model of acute myeloid leukemia progression using CRISPR, identifying potential therapeutic targets for early disease stages. The study may lead to improved biomarkers and novel treatments for AML.
Researchers found that wearable devices can identify COVID-19 cases up to seven days before diagnosis via nasal swab. The study also showed that HRV patterns normalize after diagnosis, allowing for timely interventions.
Girls who experienced emotional neglect or severe sexual abuse early in life reported riskier sexual behaviors during adolescence. The study identified four patterns of maltreatment that led to distinct trajectories of risky sexual behavior.
Researchers successfully transplanted human cadaver-derived retinal pigment epithelium (RPE) into non-human primate models, showing promise for treating macular degeneration and blindness. The study demonstrates the safety and feasibility of this approach, paving the way for potential human clinical trials.
Researchers at Mount Sinai identified three major molecular subtypes of Alzheimer's disease using RNA sequencing data from over 1,500 brain samples. These subtypes were independent of age and disease stage and corresponded to different combinations of dysregulated biological pathways leading to brain degeneration.
A study conducted by researchers from the Icahn School of Medicine at Mount Sinai found that repeated ketamine infusions significantly reduced symptom severity in individuals with chronic PTSD. The improvement was rapid and maintained for several weeks afterwards, suggesting this may be a promising treatment option for PTSD patients.
Researchers developed polygenic risk scores using genetic data from nearly 30,000 individuals, improving IBD predictions across European, Ashkenazi Jewish, Hispanic, and UK Biobank populations. Lower predictive power was seen in African ancestry due to smaller datasets and greater genetic diversity.
A study published in Thorax found that higher intake of advanced glycation end-products (AGEs) from non-seafood meats is associated with increased wheezing in children. Researchers examined data from the National Health and Nutrition Examination Survey and found a significant link between AGE intake and respiratory symptoms.
Researchers found that targeting the fas protein can prevent cancer cells from escaping immunotherapies, leading to longer-lasting positive responses and improved survival rates. By combining immunotherapies with small molecule inhibitors, bystander tumor cell killing may be potentiated to eliminate antigen-loss variants.
A chimeric hemagglutinin (HA)-based vaccine targets the proximal part of the HA protein, neutralizing diverse influenza virus strains. The vaccine has produced strong and durable results in early-stage clinical trials, eliminating the need for revaccination.
A comprehensive analysis of proteins, genes, and RNA transcription in pediatric brain tumors has provided new understanding of these tumors. The study identified two distinct subgroups of pediatric craniopharyngioma with potential therapeutic avenues for treatment.
Researchers identified new molecular mechanisms driving late-onset Alzheimer's Disease and a promising therapeutic candidate, ATP6V1A, which improved neuronal function when normalized. The study also found potential broad neuroprotective effects for ATP6V1A.
Researchers found a vaccine created to prevent melanoma recurrence is about twice as effective when patients receive two immune-boosting components, Flt3L and poly-ICLC. This combination nearly doubled the vaccine's efficacy in promoting antibodies and T cells that can later fight melanoma.
A phase 2 study found that evinacumab reduced LDL cholesterol by 50% in patients with severe hypercholesterolemia resistant to standard treatments. The therapy works through a different mechanism than existing drugs and shows promise for treating refractory hypercholesterolemia.
Empagliflozin improves heart function, reduces dilation and hypertrophy of the left ventricle, increasing ejection fraction. The medication also enhances exercise capacity and quality of life in patients with heart failure, leading to reduced hospitalization rates.
The study, published in Genes and Development, reveals the role of signaling pathways in regulating cell behavior, including proliferation, death, and migration. The research team identified new signaling outputs that function independently of established FGF signal transduction pathways, particularly in cell adhesion.
A study of nearly 2,000 Marine recruits found asymptomatic transmission of SARS-CoV-2 despite implementing best-practice public health measures. Regular testing identified carriers who could transmit the virus to others, even in settings with high compliance rates.
Researchers developed machine learning models predicting critical events and mortality in COVID-19 patients using electronic health records. The models identified key drivers of critical illness, including acute kidney injury and elevated lactate dehydrogenase, and predicted outcomes at various time windows.
A retrospective surveillance study of over 10,000 plasma samples found that more than 1.7 million New Yorkers have been infected with SARS-CoV-2, indicating the virus was present in the city before the first confirmed case. The infection fatality rate is close to 1 percent, ten times deadlier than the flu.
Scientists develop a new type of cancer immunotherapy that uses nanobiologics to train the innate immune system to eliminate tumor cells. The therapy targets the bone marrow and activates trained immunity, reprogramming bone marrow progenitor cells to produce immune cells that halt cancer growth.